1312PTHE RELATIONSHIP BETWEEN EGFR AND KRAS MUTATION STATUS AND OVERALL SURVIVAL (OS) IN THE NCIC CTG BR.26 RANDOMIZED TRIAL OF DACOMITINIB (D) VERSUS PLACEBO (P) IN PATIENTS WITH PREVIOUSLY TREATED NON SMALL CELL LUNG CANCER (NSCLC)

Abstract Aim: Dacomitinib (D) is an irreversible, pan Her inhibitor with activity in NSCLC previously treated with an EGFR TKI. Methods: BR26 was a randomized placebo controlled trial of D (45mg orally daily) versus P in NSCLC patients previously treated with chemotherapy and an EGFR TKI. The primar...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Annals of oncology 2014-09, Vol.25 (suppl_4), p.iv462-iv462
Hauptverfasser:	Ellis, P.M., Liu, G., Millward, M., Perrone, F., Shepherd, F., Seymour, L., Sun, S., Cho, B., Morabito, A., Stockler, M.R., Leighl, N.B., Lee, C., Wierzbicki, R., Favaretto, A., Tsao, M., Wilson, C.F., Taylor, I., Ding, K., Goss, G., Bradbury, P.A.
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!